my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Company Portrait
MOLOGEN AG is a biopharmaceutical company located in Berlin, Germany and specializes in the development of novel DNA-based medicines against cancer and vaccines against infectious diseases.
The international patented platform technologies MIDGE® and dSLIM® are the foundation for all business activities. The current focus is the clinical development program of MGN1703, an immunomodulator and TLR9 agonist developed for patients with metastasized solid tumors.
MOLOGEN is looking for a strategic development and marketing partner for its cancer medicine MGN1703. The partner shall have strong clinical development, registration and marketing expertise in oncology or vaccine development.
The company was founded in 1998 and was one of the first biotechnology companies to go public.
MOLOGEN AG shares are listed on the Prime Standard segment of the Frankfurt Stock Exchange (ISIN DE 0006637200).
Industrial Sectors
Contact / Request information
Contact the company and request further information free of charge:
Watchlist
This is where you can add this company to your personal favourites
MOLOGEN AG Interim Financial Report: Clinical cancer studies are progressing according to plan
In the first half of 2011, MOLOGEN AG concentrated above all on its ongoing clinical studies with the cancer medications MGN1703 and MGN1601. Both studies have progressed as planned. Meanwhile the implementation of the phase II/III colorectal cancer study with MGN1703 could also be started ... more
The Charité - Medical University of Berlin has begun the implementation of the clinical study phase I/II with the renal cancer medication MGN1601 (ASET Study). With this MOLOGEN AG product, a cell-based gene therapy for the treatment of advanced renal cancer is entering the first important ... more
Mologen extends clinical study to include another dosing group
Following positive interim results in the current clinical study with Mologen AG's cancer drug MGN1703, the authorities responsible have approved an extension of the study to include an additional dosing group. This means that the company can now start prompt investigation of the maximum do ... more
MOLOGEN AG is a biopharmaceutical company located in Berlin, Germany and specializes in the development of novel DNA-based medicines against cancer and vaccines against infectious diseases. The international patented platform technologies MIDGE® and dSLIM® are the foundation for all busin ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
